Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q32 BioFRA:DB0 +0.08%25 EV-to-OCF is -18.80 as of Aug. 22, 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,407 Biotechnology companies, Q32 Bio ranks better than 80.67% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Q32 Bio's Enterprise Value is €320.38 Mil.
Q32 Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-17.04 Mil. Therefore, Q32 Bio's EV-to-OCF for today is -18.80.
The historical rank and industry rank for Q32 Bio's EV-to-OCF or its related term are showing as below:
FRA:DB0'
s EV-to-OCF Range Over the Past 10 Years
Min: -18.67 Med: -0.76 Max: 0.78
Current: -18.67
During the past 5 years, the highest EV-to-OCF of Q32 Bio was 0.78. The lowest was -18.67. And the median was -0.76.
FRA:DB0's EV-to-OCF is ranked better than 80.67% of 1407
companies
in the Biotechnology industry
Industry Median: -3.61
vs FRA:DB0: -18.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Q32 Bio's share price for today is €13.07.
Q32 Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.662.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Q32 Bio EV-to-OCF Related Terms
Q32 Bio EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Q32 Bio's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Q32 Bio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Q32 Bio's EV-to-OCF falls into.
Q32 Bio's current Enterprise Value is €320.38 Mil.
Q32 Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q32 Bio (FRA:DB0) has a EV-to-OCF of -18.80 as of Aug. 22, 2026. According to the industry distribution chart, Q32 Bio ranks #272 out of 1407 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Q32 Bio's EV-to-OCF too high?
Q32 Bio's current EV-to-OCF is -18.80. Based on the distribution chart, Q32 Bio ranks #272 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's EV-to-OCF compare to KYTX and PRTA?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #272 out of 1407 companies for EV-to-OCF. This places Q32 Bio in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Q32 Bio's current EV-to-OCF is -18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current EV-to-OCF of -18.80. The current EV-to-OCF is -18.80. Q32 Bio's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current EV-to-OCF is -18.80 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
25GF Score
Get the complete analysis for FRA:DB0
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DB0 has been successfully added to your 
